ME01908B - Novi antagonisti ccr2 receptora i njihova primjena - Google Patents

Novi antagonisti ccr2 receptora i njihova primjena

Info

Publication number: ME01908B
Authority: ME; Montenegro
Prior art keywords: ingelheim; rhein; receptor antagonists; gmbh; ccr2 receptor
Prior art date: 2009-12-17

Application number

MEP-2014-106A

Other languages

English (en)

Inventor

Heiner Ebel

Sara Frattini

Kai Gerlach

Riccardo Giovannini

Christoph Hoenke

Rocco Mazzaferro

Marco Santagostino

Stefan Scheuerer

Christofer Tautermann

Thomas Trieselmann

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-17

Filing date

2010-12-13

Publication date

2014-12-20

2010-12-13 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2014-12-20 Publication of ME01908B publication Critical patent/ME01908B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

Description

"(12) PATENTNI SPIS 1 me B 01908 ME (11) ME 01908B (19) Crna Gora (21) Broj prijave: P-2014-106 (22) Datum podnošenja prijave: 13. 12. 2010 (45) Datum objavljivanja patenta: 20. 12. 2014 Glasnik : 16/2014 (51) Me dunarodna klasifikacija MKP C07D491/107 2006.01 C07D405/14 2006.01 A61K31/506 2006.01 A61P29/00 2006.01 (30) Me dunarodno pravo prvenstva / EP / 20090179555 17. 12. 2009 / EP / 20100162621 12. 05. 2010 (96) Broj i datum prijave evropskog patenta: / 10796336.5 13. 12. 2010 (86) Broj i datum me dunarodne prijave: / PCT/EP2010/069549 13. 12. 2010 (73) Nosilac Patenta , Boehringer Ingelheim International GmbH , Binger Strasse 173 , 55216 Ingelheim am Rhein , DE (74) Zastupnik: , RADULOVI C, S. Božidar , Studentska bb, Lamela 3/18 , 81000 Podgorica , ME (72) Pronalaza c , EBEL, Heiner , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , FRATTINI, Sara , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , GERLACH, Kai , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , GIOVANNINI, Riccardo , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , HOENKE, Christoph , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , MAZZAFERRO, Rocco , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , SANTAGOSTINO, Marco , BOEHRINGER INGELHEIM GMBH, Corporate Patent, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , SCHEUERER, Stefan , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , TAUTERMANN, Christofer , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , TRIESELMANN, Thomas , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE (54) Naziv: me NOVI ANTAGONISTI CCR2 RECEPTORA I NJIHOVA PRIMJENA en NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF"

MEP-2014-106A 2009-12-17 2010-12-13 Novi antagonisti ccr2 receptora i njihova primjena ME01908B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP09179555		2009-12-17
EP10162621		2010-05-12
EP10796336.5A EP2513093B1 (en)	2009-12-17	2010-12-13	New ccr2 receptor antagonists and uses thereof
PCT/EP2010/069549 WO2011073154A1 (en)	2009-12-17	2010-12-13	New ccr2 receptor antagonists and uses thereof

Publications (1)

Publication Number	Publication Date
ME01908B true ME01908B (me)	2014-12-20

Family

ID=43533115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2014-106A ME01908B (me)	2009-12-17	2010-12-13	Novi antagonisti ccr2 receptora i njihova primjena

Country Status (36)

Country	Link
US (6)	US8765949B2 (me)
EP (3)	EP3091012B1 (me)
JP (1)	JP5632014B2 (me)
KR (1)	KR101530234B1 (me)
CN (1)	CN102933579B (me)
AP (1)	AP3170A (me)
AR (1)	AR079636A1 (me)
AU (1)	AU2010332969B2 (me)
BR (1)	BR112012015873B1 (me)
CA (1)	CA2782464C (me)
CL (1)	CL2012001311A1 (me)
CO (1)	CO6650336A2 (me)
CY (1)	CY1115873T1 (me)
DK (1)	DK2513093T3 (me)
EA (1)	EA024397B1 (me)
EC (1)	ECSP12012010A (me)
ES (2)	ES2674275T3 (me)
GE (1)	GEP20146124B (me)
HR (1)	HRP20141143T1 (me)
IL (1)	IL219421A (me)
MA (1)	MA33818B1 (me)
ME (1)	ME01908B (me)
MX (2)	MX346393B (me)
MY (1)	MY160471A (me)
NZ (1)	NZ599770A (me)
PE (1)	PE20121614A1 (me)
PH (1)	PH12012501215A1 (me)
PL (2)	PL3091012T3 (me)
PT (2)	PT3091012T (me)
RS (1)	RS53555B1 (me)
SG (1)	SG181722A1 (me)
SI (1)	SI2513093T1 (me)
TN (1)	TN2012000300A1 (me)
TW (1)	TWI473800B (me)
UY (1)	UY33109A (me)
WO (1)	WO2011073154A1 (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2687931C (en)	2007-05-31	2016-05-24	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
EA020548B1 (ru)	2008-12-19	2014-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
MX346393B (es)	2009-12-17	2017-03-17	Centrexion Therapeutics Corp	Nuevos antagonistas del receptor ccr2 y usos de los mismo.
WO2011141474A1 (en)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja)	2010-05-12	2014-12-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011144501A1 (en)	2010-05-17	2011-11-24	Boehringer Ingelheim International Gmbh	Ccr2 antagonists and uses thereof
EP2576542B1 (en)	2010-05-25	2015-04-22	Boehringer Ingelheim International GmbH	Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
WO2011151251A1 (en)	2010-06-01	2011-12-08	Boehringer Ingelheim International Gmbh	New ccr2 antagonists
WO2012171863A1 (en) *	2011-06-16	2012-12-20	Boehringer Ingelheim International Gmbh	New selective ccr2 antagonists
WO2013010839A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Novel and selective ccr2 antagonists
WO2013060865A1 (en)	2011-10-28	2013-05-02	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en)	2012-05-10	2014-11-04	Stan S. Sastry	Managing and treating keloids
WO2016081801A1 (en) *	2014-11-21	2016-05-26	Millennium Pharmaceuticals, Inc.	Use of an anti-ccr2 antagonist in the treatment of an infectious disease
BR112017024555A2 (pt) *	2015-05-21	2018-07-24	Chemocentryx Inc	moduladores de ccr2
WO2017004537A1 (en) *	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
JP2019517523A (ja)	2016-06-03	2019-06-24	ケモセントリックス，インコーポレイテッド	肝線維症を治療する方法
US10195188B2 (en)	2016-06-13	2019-02-05	Chemocentryx, Inc.	Method of treating pancreatic cancer
SG10202012434QA (en) *	2016-06-13	2021-01-28	Chemocentryx Inc	Methods of treating pancreatic cancer
CN108017599B (zh) *	2016-11-04	2020-03-03	上海爱科百发生物医药技术有限公司	[3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
NZ753802A (en)	2016-11-23	2025-10-31	Chemocentryx Inc	Method of treating focal segmental glomerulosclerosis
EP3824906A1 (en)	2016-12-21	2021-05-26	Amgen Inc.	Anti-tnf alpha antibody formulations
KR102677442B1 (ko)	2017-09-25	2024-06-20	케모센트릭스, 인크.	케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법
AU2018347361A1 (en)	2017-10-11	2020-04-30	Chemocentryx, Inc.	Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
MA50423A (fr)	2018-01-08	2020-08-26	Chemocentryx Inc	Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
US20210322412A1 (en) *	2020-04-20	2021-10-21	Centrexion Therapeutics Corporation	Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) *	2020-10-20	2022-06-16	Lumicks Ca Holding B V	Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US213428A (en) *		1879-03-18		Improvement in harrow-teeth
US568885A (en) *		1896-10-06		Can-seaming mechanism
US4032526A (en)	1975-10-02	1977-06-28	American Cyanamid Company	1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en)	1980-02-13	1984-01-17	Sankyo Company Limited	4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de)	1985-05-15	1986-11-20	Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München	Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (me)	1985-11-07	1988-06-01
JPS61165445A (ja)	1986-01-08	1986-07-26	株式会社巴組鐵工所	振動を減少しうる床構造
US5096916A (en)	1990-05-07	1992-03-17	Aegis Technology, Inc.	Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
EP0665833B1 (en)	1992-10-23	1999-07-14	MERCK SHARP & DOHME LTD.	Dopamine receptor subtype ligands
JP3166376B2 (ja)	1993-02-03	2001-05-14	松下電器産業株式会社	熱利用装置
US5629235A (en)	1995-07-05	1997-05-13	Winbond Electronics Corporation	Method for forming damage-free buried contact
TW531537B (en)	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5629325A (en)	1996-06-06	1997-05-13	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en)	1996-06-06	2002-08-20	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en)	2001-12-07	2005-12-27	Pharmacia Corporation	Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
HU226859B1 (en)	1997-10-27	2009-12-28	Neurosearch As	Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
ES2219092T3 (es)	1998-11-20	2004-11-16	G.D. Searle Llc	Proceso para fabricar pirazoles 5-substituidos usando ditietanos.
US6248755B1 (en)	1999-04-06	2001-06-19	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
HUP0202867A3 (en)	1999-05-04	2004-01-28	Schering Corp	Piperazine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
US20020045613A1 (en)	2000-04-27	2002-04-18	Heinz Pauls	1-aroyl-piperidinyl benzamidines
PL360495A1 (en)	2000-05-22	2004-09-06	Aventis Pharmaceuticals Inc.	Arylmethylamine derivatives for use as tryptase inhibitors
IL155335A0 (en)	2000-10-12	2003-11-23	Boehringer Ingelheim Pharma	Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
AR035700A1 (es)	2001-05-08	2004-06-23	Astrazeneca Ab	Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
KR100971616B1 (ko)	2001-06-22	2010-07-22	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2002363236A1 (en)	2001-10-30	2003-05-12	Millennium Pharmaceuticals, Inc.	Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en)	2001-12-17	2004-10-19	Sunesis Pharmaceuticals, Inc.	Small-molecule inhibitors of interleukin-2
BR0307429A (pt)	2002-02-05	2004-12-28	Novo Nordisk As	Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
JP2003240776A (ja)	2002-02-13	2003-08-27	Horiba Ltd	クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu)	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en)	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
KR20040090978A (ko)	2002-03-13	2004-10-27	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
US20040014744A1 (en)	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
EP1498125A4 (en)	2002-04-24	2008-08-20	Takeda Pharmaceutical	USE OF COMPOUNDS WITH CCR ANTAGONISM
ATE396993T1 (de)	2002-04-29	2008-06-15	Merck & Co Inc	Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
BR0311619A (pt)	2002-06-05	2005-03-08	Pharmacia Corp	Derivados de pirazol como inibidores de cinase p38
WO2004024710A1 (en)	2002-09-13	2004-03-25	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv)	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Coumpounds
GB0229618D0 (en)	2002-12-19	2003-01-22	Cancer Rec Tech Ltd	Pyrazole compounds
US20040147561A1 (en)	2002-12-27	2004-07-29	Wenge Zhong	Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) *	2003-02-14	2004-09-02	Smithkline Beecham Corporation	Ccr8 antagonists
HRP20050895B1 (hr)	2003-03-12	2014-06-06	Kudos Pharmaceuticals Limited	Ftalazinon derivati
DK1615909T3 (da)	2003-04-23	2008-11-17	Glaxo Group Ltd	Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme
FR2854158B1 (fr)	2003-04-25	2006-11-17	Sanofi Synthelabo	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
ATE370135T1 (de)	2003-07-18	2007-09-15	Glaxo Group Ltd	Substituierte piperidine als histamin-h3- rezeptorliganden
WO2005009976A1 (en)	2003-07-29	2005-02-03	Novo Nordisk A/S	Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
UA82917C2 (en)	2003-12-18	2008-05-26		3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
GB0403155D0 (en)	2004-02-12	2004-03-17	Vernalis Res Ltd	Chemical compounds
EP1720545B1 (en)	2004-03-03	2014-10-29	ChemoCentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
PE20060285A1 (es)	2004-03-30	2006-05-08	Aventis Pharma Inc	Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
EP1761496A2 (en)	2004-03-31	2007-03-14	Janssen Pharmaceutica N.V.	Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
AU2005257859A1 (en)	2004-05-21	2006-01-05	Merck & Co., Inc.	Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
MXPA06013996A (es)	2004-06-02	2007-02-08	Takeda Pharmaceutical	Compuesto heterociclico fusionado.
FR2871157A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Produits biaryl aromatiques, compositions les contenant et utilisation
EP1758580A4 (en)	2004-06-24	2008-01-16	Incyte Corp	N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
MX2007000036A (es)	2004-06-25	2007-05-18	Johnson & Johnson	Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
CN1976707A (zh) *	2004-06-28	2007-06-06	因赛特公司	作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
GEP20094844B (en) *	2004-06-28	2009-11-25	Incyte Corp	3-aminocyclopentane carboxamides as modulators of chemokine receptors
AU2005276229A1 (en)	2004-08-26	2006-03-02	Kudos Pharmaceuticals Limited	4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en)	2004-09-17	2004-10-20	Glaxo Group Ltd	Novel compounds
MX2007003325A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
WO2006038734A1 (en)	2004-10-08	2006-04-13	Astellas Pharma Inc.	Pyridazinone derivatives cytokines inhibitors
CA2589106C (en)	2004-11-02	2015-07-21	Northwestern University	Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
PA8653301A1 (es)	2004-11-22	2006-11-09	Incyte Corp Incyte Corp	Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de)	2004-12-22	2006-07-06	Bayer Healthcare Ag	Cyanoguanidin-substituierte Pyrazoline
US7919495B2 (en)	2005-02-17	2011-04-05	Astellas Pharma, Inc.	Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
WO2006113261A2 (en)	2005-04-14	2006-10-26	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US20070032475A1 (en)	2005-04-15	2007-02-08	Ye Xiaocong M	Novel compounds useful for bradykinin B1 receptor antagonism
CA2606288A1 (en)	2005-04-18	2006-10-26	Neurogen Corporation	Subtituted heteroaryl cb1 antagonists
ZA200710379B (en)	2005-05-20	2009-05-27	Vertex Pharma	Pyrrolopyridines useful as inhibitors of protein kinase
EP2233470B1 (en)	2005-07-04	2011-12-07	High Point Pharmaceuticals, LLC	Histamine H3 receptor antagonists
CA2606004A1 (en)	2005-08-02	2007-02-08	Neurogen Corporation	Dipiperazinyl ketones and related analogues
GB0517184D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AR055203A1 (es)	2005-08-31	2007-08-08	Otsuka Pharma Co Ltd	Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en) *	2005-09-06	2008-01-01	Astrazeneca Ab	Novel compounds
KR101415426B1 (ko)	2005-09-27	2014-07-04	아이알엠 엘엘씨	디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US20100016289A1 (en)	2005-11-01	2010-01-21	Kevin Sprott	Compounds Useful as Antagonists of CCR2
WO2007053498A1 (en)	2005-11-01	2007-05-10	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of ccr2
JP2009515904A (ja)	2005-11-14	2009-04-16	アイアールエム・リミテッド・ライアビリティ・カンパニー	Ｌｘｒモジュレーターとしての化合物および組成物
EP1970373A1 (en) *	2005-12-02	2008-09-17	Mitsubishi Tanabe Pharma Corporation	Alicyclic heterocyclic compound
AU2006329007A1 (en)	2005-12-20	2007-06-28	Novartis Ag	Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IL172838A (en)	2005-12-27	2010-06-16	Joma Int As	Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en)	2006-01-17	2007-07-26	Kalypsys, Inc.	Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
NZ570847A (en)	2006-02-28	2011-10-28	Helicon Therapeutics Inc	Therapeutic compounds
JP2009530261A (ja)	2006-03-16	2009-08-27	ファイザー・プロダクツ・インク	ピラゾール化合物
AU2007238878A1 (en)	2006-04-11	2007-10-25	Merck Sharp & Dohme Corp.	Diaryl substituted alkanes
US7807671B2 (en)	2006-04-25	2010-10-05	Bristol-Myers Squibb Company	Diketo-piperazine and piperidine derivatives as antiviral agents
EP2015751A2 (en)	2006-04-28	2009-01-21	Northwestern University	Salts of pyridazine compounds
JP2009541268A (ja)	2006-06-22	2009-11-26	ビオヴィトルム・アクチボラゲット（プブリクト）	Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
WO2008014199A2 (en)	2006-07-28	2008-01-31	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the cb2 receptor
GB0617575D0 (en)	2006-09-06	2006-10-18	Syngenta Ltd	Herbicidal compounds and compositions
JP5030114B2 (ja)	2006-09-25	2012-09-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体をモジュレートする化合物
US8754107B2 (en)	2006-11-17	2014-06-17	Abbvie Inc.	Aminopyrrolidines as chemokine receptor antagonists
CN103690542B (zh)	2006-12-28	2015-11-18	Abbvie公司	聚(adp-核糖)聚合酶抑制剂
JP2010518064A (ja)	2007-02-12	2010-05-27	メルク・シャープ・エンド・ドーム・コーポレイション	Ａｄおよび関連状態の治療のためのピペラジン誘導体
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
FR2915552B1 (fr)	2007-04-27	2009-11-06	Technip France	Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
CA2687931C (en)	2007-05-31	2016-05-24	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
CA2691662A1 (en)	2007-07-02	2009-01-08	F. Hoffmann-La Roche Ag	Imidazole derivatives as ccr2 receptor antagonists
US7977358B2 (en)	2007-07-26	2011-07-12	Hoffmann-La Roche Inc.	Pyrazol derivatives
JP5303557B2 (ja)	2007-08-22	2013-10-02	アイアールエム・リミテッド・ライアビリティ・カンパニー	キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体
BRPI0817935A2 (pt)	2007-10-01	2015-04-07	Hoffmann La Roche	Derivados de biarila
EP2203437B1 (en)	2007-10-09	2012-11-07	F. Hoffmann-La Roche AG	Chiral cis-imidazolines
CN101820789A (zh)	2007-10-12	2010-09-01	黄钟午	鞋带捆绑工具
WO2009067406A1 (en)	2007-11-20	2009-05-28	Janssen Pharmaceutica N.V.	Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en)	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2062889A1 (de)	2007-11-22	2009-05-27	Boehringer Ingelheim Pharma GmbH & Co. KG	Verbindungen
EP2225223B1 (de) *	2007-11-22	2017-01-11	Boehringer Ingelheim International GmbH	Organische verbindungen
AU2009259496A1 (en)	2008-06-18	2009-12-23	F. Hoffmann-La Roche Ag	Novel heteroaryl carboxamide derivatives
KR20110092266A (ko)	2008-08-04	2011-08-17	씨에이치디아이 파운데이션, 인코포레이티드	소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
GB0815369D0 (en)	2008-08-22	2008-10-01	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
EP2331506B1 (de)	2008-09-02	2013-07-03	Boehringer Ingelheim International GmbH	Neue benzamide, deren herstellung und deren verwendung als arzneimittel
EP2342199B1 (en)	2008-09-25	2014-02-26	Boehringer Ingelheim International GmbH	Sulfonyl compounds which selectively modulate the CB2 receptor
EA020548B1 (ru) *	2008-12-19	2014-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
CA2750635A1 (en)	2009-02-23	2010-08-26	Merck Canada Inc.	Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
MX346393B (es)	2009-12-17	2017-03-17	Centrexion Therapeutics Corp	Nuevos antagonistas del receptor ccr2 y usos de los mismo.
US20130143905A1 (en)	2009-12-17	2013-06-06	Boehringer Ingelheim International Gmbh	Novel antagonists for ccr2 and uses thereof
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
JP5646736B2 (ja)	2010-05-12	2014-12-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011141474A1 (en)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en)	2010-05-17	2011-11-24	Boehringer Ingelheim International Gmbh	Ccr2 antagonists and uses thereof
EP2576542B1 (en)	2010-05-25	2015-04-22	Boehringer Ingelheim International GmbH	Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
WO2011151251A1 (en)	2010-06-01	2011-12-08	Boehringer Ingelheim International Gmbh	New ccr2 antagonists
WO2012171863A1 (en)	2011-06-16	2012-12-20	Boehringer Ingelheim International Gmbh	New selective ccr2 antagonists
WO2013010839A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Novel and selective ccr2 antagonists
JP6229575B2 (ja)	2014-03-31	2017-11-15	京セラドキュメントソリューションズ株式会社	画像処理装置
WO2017004537A1 (en) *	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate

2010
- 2010-12-13 MX MX2013008863A patent/MX346393B/es unknown
- 2010-12-13 PT PT161570270T patent/PT3091012T/pt unknown
- 2010-12-13 PL PL16157027T patent/PL3091012T3/pl unknown
- 2010-12-13 DK DK10796336.5T patent/DK2513093T3/da active
- 2010-12-13 EP EP16157027.0A patent/EP3091012B1/en active Active
- 2010-12-13 BR BR112012015873-2A patent/BR112012015873B1/pt not_active IP Right Cessation
- 2010-12-13 PL PL10796336T patent/PL2513093T3/pl unknown
- 2010-12-13 RS RS20140526A patent/RS53555B1/sr unknown
- 2010-12-13 EP EP14177921.5A patent/EP2813503B1/en not_active Not-in-force
- 2010-12-13 CA CA2782464A patent/CA2782464C/en active Active
- 2010-12-13 SG SG2012044129A patent/SG181722A1/en unknown
- 2010-12-13 KR KR1020127014412A patent/KR101530234B1/ko active Active
- 2010-12-13 GE GEAP201012789A patent/GEP20146124B/en unknown
- 2010-12-13 CN CN201080057415.2A patent/CN102933579B/zh active Active
- 2010-12-13 AP AP2012006276A patent/AP3170A/xx active
- 2010-12-13 ES ES16157027.0T patent/ES2674275T3/es active Active
- 2010-12-13 HR HRP20141143AT patent/HRP20141143T1/hr unknown
- 2010-12-13 MY MYPI2012002736A patent/MY160471A/en unknown
- 2010-12-13 AU AU2010332969A patent/AU2010332969B2/en active Active
- 2010-12-13 WO PCT/EP2010/069549 patent/WO2011073154A1/en not_active Ceased
- 2010-12-13 MX MX2012006964A patent/MX2012006964A/es active IP Right Grant
- 2010-12-13 SI SI201030770T patent/SI2513093T1/sl unknown
- 2010-12-13 JP JP2012543667A patent/JP5632014B2/ja active Active
- 2010-12-13 PH PH1/2012/501215A patent/PH12012501215A1/en unknown
- 2010-12-13 PT PT107963365T patent/PT2513093E/pt unknown
- 2010-12-13 ES ES10796336.5T patent/ES2524829T3/es active Active
- 2010-12-13 EP EP10796336.5A patent/EP2513093B1/en active Active
- 2010-12-13 PE PE2012000827A patent/PE20121614A1/es active IP Right Grant
- 2010-12-13 ME MEP-2014-106A patent/ME01908B/me unknown
- 2010-12-13 NZ NZ599770A patent/NZ599770A/en not_active IP Right Cessation
- 2010-12-13 EA EA201200876A patent/EA024397B1/ru not_active IP Right Cessation
- 2010-12-16 US US12/969,745 patent/US8765949B2/en active Active
- 2010-12-16 AR ARP100104699A patent/AR079636A1/es not_active Application Discontinuation
- 2010-12-16 TW TW99144272A patent/TWI473800B/zh not_active IP Right Cessation
- 2010-12-16 UY UY33109A patent/UY33109A/es not_active Application Discontinuation
2012
- 2012-04-25 IL IL219421A patent/IL219421A/en active IP Right Grant
- 2012-05-18 CL CL2012001311A patent/CL2012001311A1/es unknown
- 2012-06-13 TN TNP2012000300A patent/TN2012000300A1/en unknown
- 2012-06-14 MA MA34961A patent/MA33818B1/fr unknown
- 2012-06-15 CO CO12101565A patent/CO6650336A2/es active IP Right Grant
- 2012-06-28 EC ECSP12012010 patent/ECSP12012010A/es unknown
2014
- 2014-04-24 US US14/260,552 patent/US9670222B2/en active Active
- 2014-11-12 CY CY20141100939T patent/CY1115873T1/el unknown
2017
- 2017-05-26 US US15/606,749 patent/US10196402B2/en active Active
2018
- 2018-12-27 US US16/233,315 patent/US11046706B2/en active Active
2021
- 2021-06-11 US US17/345,110 patent/US11731981B2/en active Active
2023
- 2023-07-31 US US18/362,028 patent/US12209094B2/en active Active

Also Published As

Publication number	Publication date
HRP20141143T1 (hr)	2015-01-02
MY160471A (en)	2017-03-15
CN102933579A (zh)	2013-02-13
US9670222B2 (en)	2017-06-06
TWI473800B (zh)	2015-02-21
CL2012001311A1 (es)	2012-10-12
US10196402B2 (en)	2019-02-05
NZ599770A (en)	2014-06-27
JP5632014B2 (ja)	2014-11-26
US11731981B2 (en)	2023-08-22
DK2513093T3 (da)	2014-09-29
US20120004252A1 (en)	2012-01-05
BR112012015873B1 (pt)	2021-06-01
BR112012015873A2 (pt)	2019-09-24
EP2813503B1 (en)	2016-04-20
AU2010332969B2 (en)	2015-02-12
KR101530234B1 (ko)	2015-06-19
EP2513093B1 (en)	2014-08-27
EA201200876A1 (ru)	2013-01-30
CO6650336A2 (es)	2013-04-15
IL219421A (en)	2015-07-30
GEP20146124B (en)	2014-07-25
EP2813503A1 (en)	2014-12-17
US12209094B2 (en)	2025-01-28
ECSP12012010A (es)	2012-08-31
PL3091012T3 (pl)	2018-08-31
EP2513093A1 (en)	2012-10-24
SG181722A1 (en)	2012-07-30
RS53555B1 (sr)	2015-02-27
MA33818B1 (fr)	2012-12-03
CN102933579B (zh)	2015-07-15
US20170362249A1 (en)	2017-12-21
MX2012006964A (es)	2012-07-17
US20190300541A1 (en)	2019-10-03
US20140235661A1 (en)	2014-08-21
US8765949B2 (en)	2014-07-01
PT2513093E (pt)	2014-10-22
PL2513093T3 (pl)	2015-03-31
US20240109909A1 (en)	2024-04-04
HK1178147A1 (en)	2013-09-06
PH12012501215A1 (en)	2015-11-13
US11046706B2 (en)	2021-06-29
KR20120123652A (ko)	2012-11-09
AR079636A1 (es)	2012-02-08
UY33109A (es)	2011-07-29
CA2782464A1 (en)	2011-06-23
EP3091012A1 (en)	2016-11-09
TN2012000300A1 (en)	2013-12-12
PT3091012T (pt)	2018-06-27
JP2013514301A (ja)	2013-04-25
ES2674275T3 (es)	2018-06-28
ES2524829T3 (es)	2014-12-12
CA2782464C (en)	2016-11-29
US20220002310A1 (en)	2022-01-06
PE20121614A1 (es)	2012-12-21
EA024397B1 (ru)	2016-09-30
TW201130816A (en)	2011-09-16
SI2513093T1 (sl)	2014-11-28
WO2011073154A1 (en)	2011-06-23
AP3170A (en)	2015-03-31
IL219421A0 (en)	2012-06-28
MX346393B (es)	2017-03-17
CY1115873T1 (el)	2017-01-25
EP3091012B1 (en)	2018-04-11
AP2012006276A0 (en)	2012-06-30
AU2010332969A1 (en)	2012-05-31

Publication	Publication Date	Title
ME01908B (me)	2014-12-20	Novi antagonisti ccr2 receptora i njihova primjena
BRPI0918789A2 (pt)	2017-05-30	variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
BR112012005736A2 (pt)	2016-03-08	di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI0918492A2 (pt)	2015-12-01	uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
PT2547679E (pt)	2016-01-27	Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BR112012015043A2 (pt)	2017-03-01	manta fibrosa não tecida dimensionalmente estável, fibras finas produzidas por sopro em fusão (meltblown), e métodos de fabricação e uso das mesmas
BRPI0813225A2 (pt)	2014-12-23	Catalisador de craqueamento catalítico e preparação e uso do mesmo.
BRPI1011346A2 (pt)	2016-10-18	partícula de polímero, composição tensoativa, processos de formação de partículas de polímero, e, uso das mesmas
BRPI0813897A2 (pt)	2014-12-30	Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos.
BRPI0911938A2 (pt)	2015-10-20	composição, líquido de diálise, uso do líquido de diálise, e, preparação combinada
BRPI0924177A2 (pt)	2015-08-18	Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI1010957A2 (pt)	2018-02-06	variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
BRPI0806589A2 (pt)	2014-05-13	Catalisador, sua preparação e uso.
BRPI1014800A8 (pt)	2016-10-11	"composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas"
BRPI0810872A2 (pt)	2014-10-29	Processos para a cristalização de um composto, e para a produção de partículas escoáveis ou desepjáveis de um composto, particula escoável ou despejável de um composto, e, uso das partículas escoáveis ou despejáveis de um composto.
IL215603A0 (en)	2011-12-29	Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
IT1393709B1 (it)	2012-05-08	Struttura composita tessutale, particolarmente per l'uso quale mezzo filtrante.
BR112012016882A2 (pt)	2018-06-05	"monólitos de polímero poroso, processos para preparação e uso dos mesmos"
BRPI1009481A2 (pt)	2016-03-01	compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
BRPI0808098A2 (pt)	2014-06-17	4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0914488A2 (pt)	2015-10-27	"composições de limpeza incluindo siloxanos de sorbitano modificados e uso das mesmas"
BRPI0808025A2 (pt)	2014-06-24	Composto de benzimidazol e uso farmacêutico do mesmo
MA28575B1 (fr)	2007-05-02	Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique
ITVR20040082A1 (it)	2004-08-11	Macchina per la pulitura di pavimenti particolarmente per uso industriale
CL2008001985A1 (es)	2008-11-03	Uso de compuestos derivados de benzoxazol, benzimidazol y benzotiazol en la prevencion, tratamiento o inhibicion de una afeccion inflamatoria de la piel o afeccion asociada con la disminucion de colageno.